Companies /Healthcare

Abbvie Inc

NYSE: ABBV Drug Manufacturers - General
$256.37
▼ $3.84 (−1.48%) today
Markets closed · 5:29pm ET

Q3 2025 Earnings

Reported Oct 31, 2025, 7:51am ET · SEC source
$1.86
Beat +4.23%
EPS · est. $1.78
$15.8B
Beat +1.23%
Revenue · est. $15.6B
+5.3%
Beating market
ABBV vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−4%−2%0+2%Oct 31Oct 31report 7:51am ETearnings−0.6%−3.8%
−4%−2%0+2%Oct 31Oct 31earnings−0.6%−3.8%
ABBV −3.8%S&P 500 −0.6%
−4%−2%0+2%Oct 31Oct 31report 7:51am ETearnings−0.9%−3.8%
−4%−2%0+2%Oct 31Oct 31earnings−0.9%−3.8%
ABBV −3.8%NASDAQ −0.9%
−6%−3%0Oct 30Nov 7report 7:51am ETearnings−2.0%−3.1%
−6%−3%0Oct 30Nov 7earnings−2.0%−3.1%
ABBV −3.1%S&P 500 −2.0%
−6%−3%0Oct 30Nov 7report 7:51am ETearnings−3.7%−3.1%
−6%−3%0Oct 30Nov 7earnings−3.7%−3.1%
ABBV −3.1%NASDAQ −3.7%
−4.45%
Day of report
−2.79%
Next session
+0.51%
One week
+5.60%
30 days

S&P 500 over the same 30 days: +0.27%.

Did ABBV Beat Earnings? Q3 2025 Results

AbbVie posted a convincing third-quarter beat, reporting adjusted EPS of $1.86 against a consensus estimate of $1.78, a 4.23% positive surprise, while net revenues of $15.78 billion topped the $15.58 billion estimate by 1.23% and climbed 9.1% year over year. The headline driver was unmistakably the immunology franchise, which generated $7.88 billion in revenue with Skyrizi surging 46.8% to $4.71 billion and Rinvoq advancing 35.3% to $2.18 billion, more than compensating for Humira's continued biosimilar-driven erosion to $993 million. Neuroscience added further momentum, growing 20.2% to $2.84 billion across a broad set of contributors. The quarter was not without complexity; a $2.68 billion acquired IPR&D charge tied largely to the Capstan Therapeutics acquisition weighed heavily on GAAP results. Still, management expressed enough confidence in the underlying business to raise full-year 2025 adjusted EPS guidance to $10.61 to $10.65, while also announcing a 5.5% dividend increase to $1.73 per share quarterly.

Key Takeaways
  • Skyrizi revenue growth of 46.8% driven by continued strong uptake across immunology indications
  • Rinvoq revenue growth of 35.3% with expanding indications and market penetration
  • Neuroscience portfolio growth of 20.2% led by Botox Therapeutic, Qulipta, and Ubrelvy
  • Strong U.S. revenue growth of 8.2% and international revenue growth of 12.0%

“AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio. We are also making great progress advancing our pipeline and investing in innovation to support AbbVie's long-term growth.”

AbbVie CEO, on the earnings call

Forward Guidance & Outlook

AbbVie raised its full-year 2025 adjusted diluted EPS guidance from $10.38-$10.58 to $10.61-$10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through Q3 2025. The 2025 guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond Q3 2025, as both cannot be reliably forecasted.

ABBV YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$5.0B$10.0B$15.0B$14.5B$15.8BRevenue$10.2B$10.5BGross Profit$3.8B$1.9BOperating Income$1.6B$186.0MNet Income
$0$5.0B$10.0B$15.0BRevenueGross ProfitOperating IncomeNet Income

ABBV Revenue by Segment

Immunology$7.9B+11.9%
Skyrizi$4.7B+46.8%
Neuroscience$2.8B+20.2%
Rinvoq$2.2B+35.3%
Oncology$1.7B−0.3%
Aesthetics$1.2B−3.7%
Humira$993.0M−55.4%
Vraylar$934.0M+6.7%

ABBV Revenue by Geography

United States$12.1B
Rest of World$3.7B

Figures from SEC filings and company reports. Not investment advice.